Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

• DOI: 10.1007/s13555-023-00977-1
• Publication Date: 2023-07-31T16:02:25Z
• Authors: April W. Armstrong; Sang Hee Park; Vardhaman Patel; Malcolm Hogan; Wei-Jhih Wang; David Davidson; Viktor Chirikov
• Keywords: 03 medical and health sciences; MAIC; 0302 clinical medicine; RL1-803; Adalimumab; Indirect comparison; Deucravacitinib; Plaque psoriasis; Dermatology; Original Research

Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared long-term efficacies of deucravacitinib and adalimumab using results from extension (LTE) trials. Open-label LTE trials were identified for indirect treatment comparison (deucravacitinib: POETYK PSO-LTE [NCT04036435]; adalimumab: REVEAL [NCT00195676]). To ensure design comparability, patients initially randomized placebo switched or after week 16 compared. The primary outcome was a ≥ 75% reduction Psoriasis Area Severity Index score (PASI 75) at 112 postrandomization. Secondary outcomes PASI 75 52 90% 90) weeks 112. Missing data imputed. A matching-adjusted conducted; individual patient-level reweighted balance baseline characteristics those extension. Before reweighting, on average, (N = 329) versus 345) older, had lower body weight, received more prior systemic treatments, higher scores 90 response rates. Following adjusted rates significantly (67.2% vs. 54.0%; mean difference [95% CI], 13.2 [4.0–22.5] percentage points). Deucravacitinib numerically rate (41.3% 34.0%; 7.3 [− 2.0 16.7] treatments similar In this interim analysis, moderate severe PsO years when treated adalimumab. remained stable whereas declined year 2. Plaque inflammatory disease that causes red, itchy, dry patches (called plaques) skin. cannot be cured, but symptoms can treated. are two use psoriasis; medication injected needle under Each has proven its efficacy (a pill injection no active effect) separate clinical trials, because exactly alike, accurately Matching-adjusted method used compare one trial another direct not possible; made match patient population other trial, We performed open-label each treatment. At 1 treatment, we observed proportions receiving achieved improvement their score—called 90, respectively. proportion who greater than